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Background: Gene set analysis (GSA) methods test the association of sets of genes with phenotypes in gene
expression microarray studies. While GSA methods on a single binary or categorical phenotype abounds, little
attention has been paid to the case of a continuous phenotype, and there is no method to accommodate
correlated multiple continuous phenotypes.
Result: We propose here an extension of the linear combination test (LCT) to its new version for multiple
continuous phenotypes, incorporating correlations among gene expressions of functionally related gene sets,
as well as correlations among multiple phenotypes. Further, we extend our new method to its nonlinear
version, referred as nonlinear combination test (NLCT), to test potential nonlinear association of gene sets
with multiple phenotypes. Simulation study and a real microarray example demonstrate the practical aspects
of the proposed methods.
Conclusion: The proposed approaches are effective in controlling type I errors and powerful in testing
associations between gene-sets and multiple continuous phenotypes. They are both computationally effective.
Naively (univariately) analyzing a group of multiple correlated phenotypes could be dangerous. R-codes to
perform LCT and NLCT for multiple continuous phenotypes are available at http://www.ualberta.ca/~yyasui/
homepage.html.
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Gene-set analysisBackground
Microarray data analysis at an individual gene level usu-
ally leads to a large list of significant genes, even after
multiple comparison adjustment has been made. The
process of trying to interpret such a large list of genes is
difficult. Molecular biologists have put together lists of
genes grouped by function, such as biological pathways
or sets of genes. Various pathways or gene sets databases
have been compiled, for example, Kyoto Encyclopedia of
Genes and Genomes (KEGG) [1,2], Gene Ontology [3],
Biocarta [4] and Molecular Signature Data Base [5]. There
has been a shift in focus from gene level analysis to path-
way level, or gene set level, with many Gene Set Ana-
lysis (GSA) methods being proposed in the past decade.
The most popular one is Gene Set Enrichment Analysis* Correspondence: xiaoming@ualberta.ca
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unless otherwise stated.(GSEA) [6]. Extensive reviews and methodological dis-
cussions were given by Goeman and Buhlmann [7] and
Nam and Kim [8].
While GSA methods on a single binary or categorical
phenotype abounds, little attention has been paid to the
case of a continuous phenotype, and there are no me-
thods to accommodate correlated multiple continuous
phenotypes. Such correlated continuous variables are
measured routinely in many important clinicopathologi-
cal observations such as lung functions, tumor size or
measurements of marker proteins. A naïve approach to
analyzing such data with existing GSA methods would
be to categorize the continuous phenotypes into two
or more discrete classes, as well as analyze the multiple
correlated phenotypes univariately, i.e., one at a time.
Such artificial categorization and univariate analyses may
lead to less efficiency in gene-set analysis and even causetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cially if the multiple phenotypes exhibit relatively higher
correlations.
There is an important methodological distinction bet-
ween the competitive and self-contained GSA approaches
[6,7]. For a binary phenotype, e.g., competitive methods
use gene permutation to test whether or not the asso-
ciation of the phenotype with a gene set is similar to its as-
sociation with the other gene sets (the “Q1 hypothesis”),
while self-contained methods employ sample permutation
to test the equality of the means of the two vectors of
gene-set expressions which correspond to the two pheno-
type groups (the “Q2 hypothesis”). Here, we focused on
the self-contained methods. Unlike the gene permutation
strategy, sample permutation preserves correlation struc-
ture within gene sets and correlation structure within phe-
notypes – a key property that we wish to fully take
advantage in the proposed GSA methods.
To the best of our knowledge, although correlations
among genes in gene sets have long been observed, cor-
relation structure was considered only in a few GSA
methods. These were the modified Hotelling’s T2 test for
categorical phenotype [9], and the linear combination
test (LCT) for binary phenotype [10] and for continuous
phenotype [11]. It has been realized that incorporation
of correlations among gene expressions in a GSA ap-
proach can significantly improve efficiency of the analysis
[9]; however, it could also spell a heavy computational
burden. The linear combination test was designed to in-
corporate correlations among gene expressions while
overcome the computational burden. In the case of binary
phenotype, it has been showed that LCT was much more
computationally efficient than the modified Hotelling’s T2
test and approximated its superior power very well [10]; in
the case of continuous phenotype, it has been showed that
LCT was superior in power to the other GSA methods
under compare [11].
We propose here an extension of LCT to its new ver-
sion for multiple continuous phenotypes, incorporating
correlations among gene expressions of functionally re-
lated gene sets, as well as correlations among multiple
phenotypes. Further, we extend the new method to its
nonlinear version, referred as nonlinear combination test
(NLCT), to test potential nonlinear association between
gene sets and multiple phenotypes, especially recommen-
ded for analyzing relatively larger microarrays. The ex-
tension strategy can also be used for other GSA tools for
continuous phenotype/phenotypes, such as Global Test
[12]. The rest of the article is organized as follows. In sec-
tion 2 we give detailed derivations of the two proposed
GSA methods. In section 3, we used a simulation study to
show the practice aspects of these two proposed methods
using various settings on sample size, gene-set size, and
correlation level among genes and among phenotypes.Section 4 presents the performances of the proposed
methods on a real gene expression microarray data from
prostate tumor samples of African-American prostate
cancer patients [13].
Method
Linear combination test for multiple continuous
phenotypes
Consider a microarray study on n subjects, with mea-
surements on expressions of a predefined set of P genes
X = (x1,…, xp)
T and measurements on a group of q con-
tinuous phenotypes Y = (y1,…, yq)
T. Suppose columns in
both X and Y are centered and scaled across the sub-
jects. We are interested in testing whether there is a sig-
nificant linear relationship between the gene set X and
the group of phenotypes Y. The null hypothesis to be
tested is that expressions of the genes in the predefined
gene set X are linearly independent with the phenotypes
Y. The multivariate null hypothesis can be expressed
linearly and univariately as
H0: There is no association between any of the linear
combinations of x1,…, xp and any of the linear
combinations of y1,…, yq.
To test the linear relationship, let Z(X, A) = a1x1 +⋯ +
apxp be a linear combination of x1,…, xp, and Z(Y, B) =
b1y1 +⋯ + bqyq a linear combination of y1,…, yq, where
A ∈ Rp and B ∈ Rq represent the coefficient vectors of ai's
and bj's, respectively. For given coefficient vectors A and
B of the combination coefficients, we can focus on test-
ing whether the combination Z(X,A) is associated with
the combination Z(Y,B). This is a classical correlation
test and a commonly used test statistic is based on
measuring the Pearson correlation between Z(X,A) and
Z(Y,B), i.e. ρ = ρ(Z(X,A),Z(Y,B)). If both X and Y are nor-
mally distributed, then the statistic t ¼ ρ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃn−2ð Þ= 1−ρ2ð Þp
follows a Student's t-distribution with degrees of free-
dom n -2 under the null hypothesis [14]. This also holds
approximately if the observed values are non-normal,
provided sample size n is large enough [15].
For testing the null hypothesis H0, we consider the lin-
ear combinations of x1,…, xp and y1,…, yq, exhibiting the
highest correlation, i.e. choosing coefficient vectors A and
B to maximize the Pearson correlation between Z(X,A)
and Z(Y,B). This leads to the proposed new version of the




ρ Z X;Að Þ;Z Y ;Bð Þð Þj j2 ð1Þ
The old version of LCT for single continuous pheno-
type [11] is a special case of it.
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whose (i,j) entry is σij = cov(xi, xj); and similarly, let ΣYY =
cov(Y,Y) and ΣXY = cov(X,Y) be the covariance matrix of Y
and the covariance matrix between X and Y. The above







When the dimension of X and/or dimension of Y are
high, singularity of ΣXX and ΣYY have to be taken care of
very carefully, especially when the size of the gene set is
larger than the sample size, i.e., p > n. A possible remedy
for the singularity problem is to employ the shrinkage
technique proposed by Schafer and Strimmer [16], and
replace ΣXX and ΣYY with their shrinkage versions,
namely, ΣXX and Σ

YY . More specifically, the (i,j) entry of





, with shrinkage coefficients γij = 1, if i = j, and
γij = ρijmin(1, max(0, 1 − λ*)), if i ≠ j, where ρij is the sample
correlation between xi and xj, and the optimal shrinkage









Based on this shrinkage strategy, we get the shrinkage ver-











The computational cost on calculating (3) has to be
taken into consideration, since the right hand side is a
nonlinear programming problem involving p + q param-
eters. The computational price can be very high for
maximizing directly the right hand side of (3), especially
when permutation is used for calculating p-value of
the test. To address the computational efficiency prob-
lem, we adopt a strategy of using two groups of nor-
malized orthogonal bases, instead of using the original
observation vectors of X and Y. We perform eigenvalue
decompositions for the two shrinkage covariance matri-
ces, ΣXX ¼ UDXUT and ΣYY ¼ VDYVT , and obtain two























where α ¼ D1=2X UTA , β ¼ D1=2Y VTB and Σ ~X ~Y is the co-
variance matrix between ~X and ~Y , with its (i,j) entry be-
ing cov ~xi; ~yj
 
.The optimization problem in (4) can be solved in two
steps. Firstly, for a given β, find the optimal α, which is
proportional to Σ ~X ~Y β; secondly, substitute the optimal α
into (4), and find the global optimal β, which is propor-
tional to the first eigenvector of the matrix ΣT
~X ~Y
Σ ~X ~Y cor-
responding to the largest eigenvalue. We note that the
value of T2 * equals to the largest eigenvalue of either the
q × q matrix ΣT
~X ~Y
Σ ~X ~Y or the p × p matrix Σ
T
~Y ~X
Σ ~Y ~X . The
cost for getting the largest eigenvalue is low, providing
min(p,q) is not big.
The computation advantage is obvious when sample
permutations are used to calculate p-value of the test.
Since sample permutation changes neither the correl-
ation structure within gene sets nor the correlation
structure within phenotypes, so that we don’t need to
repeat the same eigenvalue decompositions of the two
shrinkage covariance matrices in (3) for the permuted
data, but only for the original one. In fact, after perform-
ing the eigenvalue decompositions for the two shrinkage
covariance matrices ΣXX and Σ

YY and creating two
groups of orthogonal basis vectors ~X and ~Y , permuta-
tions can be done only on ~Y directly, instead of on the
original phenol-type Y.
Nonlinear combination test for multiple continuous
phenotypes
The proposed LCT method assumes a linear relationship
between the genes in a gene set and the phenotypes. So
do almost all the self-contained GSA approaches that
have been proposed in the literature. The reason for us
to focus on testing linear relationship is mainly for sim-
plicity of the method. When we have access to limited
data points, a simpler approach could be more reliable
than a complex/flexible one. If a larger sample size is
available or if there is evidence that the relationships be-
tween gene sets and phenotypes could be non-linear/
non-monotone, we may consider relaxing the linearity
assumption, and testing more general null hypnoses, i.e.,
H0
* : there is no relationship between genes in the gene
set and the phenotypes.
The linear combination test proposed can be easily
adapted to test nonlinear relationships between genes in
a gene set and phenotypes, by using nonparametric tech-
niques. The main idea here is to apply a non-linear
transformation to the vectors of genes X, then use linear
test methods to check if there is a significant linear rela-
tionship between the non-linear transformation of X
and the phenotypes Y. This strategy is similar to that of
‘basis expansion’ which is widely adopted in regression/
discrimination analyses [17]. Some widely used non-
linear transformations are polynomial transformations
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expansions; cubic splines or wavelets transformations of
single genes. We note that the same transformation strat-
egy can be applied to the phenotypes Y. We prefer to leave
Y untransformed to avoid higher flexibility of the method,
which requires larger sample size as well as higher compu-
tational costs. In our NLCT test method used in the simu-
lation study and the real microarray example study, we
transform each gene in a gene set to a natural cubic spline
with the degree of freedom set at 5.Table 1 Type I errors of the multiple version of LCT and
NLCT GSA methods, with dimension of the multiple
phenotypes set at q = 10
Method ρ n = 20 n = 50
p = 20 p = 50 p = 100 p = 20 p = 50 p = 100
LCT 0.0 0.050 0.047 0.047 0.052 0.043 0.047
0.3 0.051 0.053 0.050 0.055 0.045 0.043
0.6 0.050 0.054 0.042 0.051 0.042 0.048
0.9 0.053 0.052 0.044 0.058 0.050 0.046
NLCT 0.0 0.041 0.039 0.035 0.062 0.049 0.058
0.3 0.042 0.047 0.051 0.061 0.052 0.043
0.6 0.044 0.062 0.047 0.052 0.049 0.042
0.9 0.050 0.060 0.049 0.044 0.053 0.051Simulation study design
Our simulation study was designed to check perform-
ance of both LCT and NLCT methods. More specifically,
we focused on the type-I-error performance and the po-
wer performance of the proposed tests, by varying gene-
set size, sample size, and correlation levels among genes
and among phenotypes.
We describe below our simulation study design. For
each gene-set of size p, a gene expression matrix Xn × p
was generated from a multivariate normal distribution.
The correlation between each pair of genes was set at p,
with values of 0.0, 0.3, 0.6, or 0.9. For each gene set, a
group of continuous phenotypes of size q were generated
from the following multivariate linear model,
Y ¼ Xβþ ε ; ð5Þ
where βp × q is a coefficient matrix, and εn × q the error
matrix generated from a multivariate normal distribu-
tion. The correlation between each pair of the errors
was set at p so that each pair of the columns in Y is cor-
related with correlation ρ. In the null model, used to
check the size of the tests, we set all entries of β to 0, so
that columns in X are not correlated with columns in Y.
In the alternative model, used to check the power of the
tests, we randomly selected five rows and three columns
of the coefficient matrix, and set the corresponding fif-
teen entries to a common value μ, ranging from 0 to 5,
with an increment of 0.25. The rest of the entries in the
coefficient matrix were set at 0. We noted that the five
selected columns of X are correlated with the three se-
lected columns of Y, and that the correlation increases
with μ. We used various sample sizes and gene-set sizes,
including large p and small n, a scenario which is com-
mon in gene-set analysis. Because the LCT and NLCT
procedures are in fact tests of correlation between two
groups of variables, ignoring which is gene group and
which is phenotype group, we set q as fix and changed p
in the simulation design. The simulation data were repli-
cated 1,000 times in each model. The p-values were cal-
culated based on 1,000 permutations.Results
Simulation study
The type I errors are similar across the LCT and NLCT
methods (Table 1), with those of LCT more closer to
nominal level of 0.05, indicating lower sample size could
lead to relatively higher type I errors of NLCT compare
to LCT.
Figure 1 illustrates the empirical power of both the
LCT and NLCT methods using the nominal level of
0.05. The top left panel (n = 20, p = 20, q = 10 and ρ =
0.0/0.3/0.6/0.9) shows power change of LCT with correl-
ation level among genes and phenotypes. At low correl-
ation levels, LCT appears to be conservative and less
powerful, which may be explained by the fact that LCT
is a test based on linear combination using shrinkage ap-
proach. Intuitively, higher level of correlation between
genes implies lower level of variability of the linear com-
bination of those genes, so does the linear combination
of phenotypes. Similar phenomenon can be found for
NLCT method on the bottom left panel (n = 50, p = 20,
q = 10 and ρ = 0.0/0.3/0.6/0.9). The top right panel (n =
50, p = 20/50/100/200, q = 10 and ρ = 0.6) shows power
change of LCT with size of gene set. It implies that, with
larger gene sets, the efficiency of LCT test drops down
significantly, i.e. larger sample size is required to test lar-
ger gene sets. The bottom right panel (n = 20/50/100/
200, p = 50, q = 10 and ρ = 0.6) shows the power change
of NLCT with sample size, indicating low sample size
could lead to very low power of test. Also comparing the
two red lines in the right panels, we can see that NLCT
is obviously less efficient than LCT when testing the linear
association between genes and phenotypes.
We have two considerations for choosing q = 10.
Firstly, the method is designed for q multiple continuous
phenotypes and we wanted to show performance of LCT
for a relatively large number of phenotypes, such as 10.
We note that q = 1 reduces to our previous publication
on LCT for a univariate phenotype. We reason that
Figure 1 Power changes of the two GSA methods: LCT and NLCT.
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lar or even better performance than q = 10. Second, the
method does not distinguish the “input” variables and
“output” variables. It is in fact a correlation test, and
from pure statistic point of view, there is no difference
in testing results (or p-values) if one considers “X as
genes and Y as phenotypes”, or if one considers “Y as
genes and X as phenotypes”. Hence, our simulation
scenarios with p = 20/50/100/200 (see upright panel of
Figure 1) can also be viewed as scenarios of q = 20/
50/100/200.
Application
Leptin is a 16-kDa protein hormone that plays a key role
in regulating energy intake and expenditure, including
appetite and hunger, metabolism and behavior. It is one
of the most important adipose-derived hormones [18].
Adiponectin (also refer to as GBP-28, apMI, AdipoQ
and Acrp30) is a protein which in humans is encoded by
ADIPOQ gene [19]. It is involved in regulating glucose
level and fatty acid oxidation. Both leptin and adiponec-
tin are well-known markers of human obesity [20-24].
They are hormones associated with various metabolic
and inflammatory conditions. Interestingly, while leptin
transcript levels are found to be over-expressed in obesesubjects, adiponectin is generally under-expressed, and
these may be observed not just in adipose but also in
other tissues. We therefore considered using the levels
of these dual markers as a multi-phenotype for applica-
tion of LCT.
We applied both LCT and NLCT to analyze a real
Affymetrix microarray dataset consisting of genome-
wide transcriptomic measurements of prostate tumor
samples from African-American prostate cancer patients
[13]. The purpose of the real microarray study was to
see the performance of the new approaches on testing
association between gene-sets and expressions of human
leptin gene (LEP) and adiponection gene (ADIPOQ). The
gene expression measurements were used as surrogate
phenotypes, since the blood serum measurements were
not available. The publicly available data were downloaded
from Gene Expression Omnibus [25] [GEO: GSE6956].
The data that we used in the present study are part
of a larger microarray study of the immunobiological
differences in prostate cancer tumors between African-
American and European-American men. Because the LEP
and ADIPOQ expression levels may be different between
the two groups, we used only the data from the African-
American group to examine the LCT and NLCT methods.
For our analysis, we used the expression values of 13,233
Wang et al. BMC Bioinformatics 2014, 15:260 Page 6 of 9
http://www.biomedcentral.com/1471-2105/15/260genes measured in tumor samples from 33 patients. The
tumor samples were resected adenocarcinomas from pa-
tients who had not received any therapy before prosta-
tectomy and were obtained from the National Cancer
Institute Cooperative Prostate Cancer Tissue Resource
(CPCTR) and the Department of Pathology at the Univer-
sity of Maryland. According to Wallace et al. [13], the
macro dissected CPCTR tumor specimens were reviewed
by a CPCTR-associated pathologist who confirmed the
presence of tumors in the specimens. The tissues were
collected between 2002 and 2004 at four different sites.
The median age of patients with prostatectomy was 61
and the median prostate-specific antigen (PSA) concentra-
tion at diagnosis was 6.1 ng/ml. Fifty-five percent of the
tumors were stage pT2, and 45% were stage pT3 or more.
Detailed RNA extraction, labeling and hybridization pro-
tocols were as described previously [13].
For comprehensive gene-set analysis, the C2 catalog
from MsigDB [6] consisting of 1,892 gene sets were used,
including metabolic and signaling pathways from major
pathway databases, gene signatures from biomedical lit-
erature including 340 PubMed articles, as well as other
gene sets compiled from published mammalian micro-
array studies. 1,846 gene sets with size range from 5 to
500 were used in our analysis. Each gene set was tested,
using both LCT and NLCT approach, for its association
with the LEP and ADIPOQ expression measurements.
First we run the univariate versions of LCT and NLCT
for each of LEP and ADIPOQ expressions, followed by
the multiple versions of LCT and NLCT for the combin-
ation of LEP and ADIPOQ, referred as a phenotype vec-
tor (LEP, ADIPOQ). Table 2 shows percentages of gene
sets with p-values less than 0.005, 0.01, 0.05, and 0.10.
We expect LCT to be more suitable than NLCT for
small to moderate sample sizes. Indeed, for our applica-
tion, LCT is more efficient than NLCT. For large sample
size and when nonlinear relationship does exist, we ex-
pect NLCT to be more efficient than LCT. A larger per-
cent of sets are associated with LEP than ADIPOQ. For
some of the sets, the association with LEP is diluted byTable 2 Percentages of gene sets with p-values less than
0.005, 0.01, 0.05 and 0.10, which from LCT/NLCT test for
univariate phenotype LEP and ADIPOQ, and multiple
phenotypes (LEP, ADIPOQ)
Method P-value
≤.005 ≤.01 ≤.05 ≤.10
LCT for LEP 2.8 4.5 19.9 36.1
LCT for ADIPOQ 0.4 0.9 3.1 6.3
LCT for (LEP, ADIPOQ) 0.9 1.5 8.6 18.6
NLCT for LEP 0.6 1.4 7.6 16.0
NLCT for ADIPOQ 0.3 0.7 3.8 10.1
NLCT for (LEP, ADIPOQ) 0.3 0.8 5.1 11.0ADIPOQ in the multiple phenotypes analysis. However,
33 sets show a p-value smaller than 0.05 in the multiple
phenotypes analysis, although their univariate analysis
indicated a p-value larger than 0.05 for each of LEP and
ADIPOQ phenotype (Table 3). The False Discovery Rates
values based on [26] were 0.04 for LEP, 0.62 for ADIPOQ,
and 0.13 for (LEP, ADIPOQ). The LCT and NLCT test
results for all gene sets possibly associated with single
phenotype LEP/ADIPOQ or the phenotype vector (LEP,
ADIPOQ) were presented in the Additional file 1.
Additional file 1 contains p-values and FDR-values
from LCT test on gene sets for LEP, ADIPOQ, and
(LEP, ADIPOQ) respectively, including all gene sets
with at least one of the three p-values less than 0.05;
while similar results from NLCT test were written in
Additional file 2.
Discussion
We focused here on self-contained GSA methods. We
note that competitive and self-contained methods test
different hypotheses, and therefore it is important for
the user to make an informed choice based on the hy-
pothesis of interest and their understanding of the limi-
tations of the two approaches (see reviews by Nam and
Kim [8] and Dinu et al. [27]). An important limitation of
the self-contained approaches is that only a few genes
can drive the association between the gene set and the
phenotypes. In such cases, post-hoc analysis can be used
to reduce the gene set to a core sub-set associated with
the phenotypes. Such an analysis has been reported in
simulations and in a real example for a single binary
phenotype [27].
Our proposed method is useful for testing associations
between sets of genes or pathways and correlated mul-
tiple continuous phenotypes. These are often measured
in molecular epidemiology studies that include clinico-
pathological measurements of tissue features such as
tumor size and staining based readouts; cellular character-
istics indicated by the amount of lymphocytic infiltration
in a tumor environment; and subject-specific measure-
ments involving diagnostic or prognostic marker protein
or metabolite concentrations. The LCT approach may still
need to be adjusted for a mixture of continuous and cat-
egorical covariates. The LEP and ADIPOQ levels in the
prostate tumor example that we have considered may also
have been influenced by patient-specific covariates such as
body mass index (BMI), age, and/or smoking status. We
note that smoking status did not show a significant as-
sociation with LEP expression levels (p-value = 0.36), or
ADIPOQ expressions levels (p-value = 0.52) in our data,
and BMI and age data were not available for our analysis.
The LCT approach can be used for both univariate
and multivariate analyses. From the real data analysis,
we can see that the univariate LCT for LEP is more
Table 3 Gene sets with LCT p-values for multiple phenotypes (LEP, ADIPOQ) less than 0.05, while p-values for univariate
phenotype LEP and ADIPOQ are larger than 0.05
Gene-set name Gene-set size LEP p-value ADIPOQ p-value (ADIPOQ, LEP) p-value
YEN_MYC_WT 8 0.061 0.199 0.034
GLUCONEOGENESIS 50 0.195 0.192 0.036
BYSTRYKH_HSC_BRAIN_TRANS_GLOCUS 144 0.118 0.157 0.047
PENG_LEUCINE_DN 135 0.186 0.189 0.035
AMINOSUGARS_METABOLISM 14 0.223 0.341 0.039
PENTOSE_PHOSPHATE_PATHWAY 21 0.192 0.098 0.044
ZELLER_MYC_UP 22 0.09 0.262 0.032
POMEROY_DESMOPLASIC_VS_CLASSIC_MD_DN 38 0.093 0.079 0.011
FBW7PATHWAY 8 0.088 0.314 0.048
GSK3PATHWAY 24 0.18 0.225 0.028
GOLDRATH_CELLCYCLE 31 0.21 0.105 0.048
STREPTOMYCIN_BIOSYNTHESIS 8 0.094 0.072 0.013
FRUCTOSE_AND_MANNOSE_METABOLISM 24 0.168 0.061 0.007
GLYCOLYSISPATHWAY 8 0.137 0.076 0.013
UBIQUINONE_BIOSYNTHESIS 12 0.086 0.051 0.013
HOFMANN_MANTEL_LYMPHOMA_VS_LYMPH_NODES_UP 45 0.053 0.135 0.022
HOGERKORP_CD44_DN 22 0.057 0.504 0.05
CROMER_HYPOPHARYNGEAL_MET_VS_NON_DN 72 0.11 0.178 0.05
RUTELLA_HEPATGFSNDCS_UP 144 0.058 0.136 0.045
METHOTREXATE_PROBCELL_DN 11 0.102 0.132 0.033
GENOTOXINS_4HRS_DISCR 33 0.194 0.121 0.03
HTERT_UP 57 0.083 0.089 0.036
METHOTREXATE_PROBCELL_UP 14 0.147 0.111 0.046
CAMPTOTHECIN_PROBCELL_UP 17 0.085 0.159 0.038
UV_UNIQUE_FIBRO_UP 20 0.058 0.343 0.014
CITED1_KO_HET_DN 29 0.097 0.157 0.012
HEATSHOCK_YOUNG_UP 11 0.113 0.268 0.042
HSA00051_FRUCTOSE_AND_MANNOSE_METABOLISM 35 0.148 0.075 0.044
HSA00052_GALACTOSE_METABOLISM 27 0.053 0.277 0.044
HSA00521_STREPTOMYCIN_BIOSYNTHESIS 10 0.099 0.124 0.026
HSA01030_GLYCAN_STRUCTURES_BIOSYNTHESIS_1 83 0.106 0.25 0.049
HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 218 0.103 0.116 0.044
HSA04120_UBIQUITIN_MEDIATED_PROTEOLYSIS 34 0.124 0.082 0.041
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Generally speaking, if we knew previously that a subset
of the group of phenotypes is more highly associated
with the gene sets than the rest of phenotypes, then fo-
cusing on the subset of the phenotypes will gain higher
power for the test, for further information is incor-
porated in the testing. Here, we want to point out that
naively (univariately) analyzing a group of multiple cor-
related phenotypes will lead to problems. In the real data
analysis, for controlling type I error (e.g. 0.05), it is hard
to set a threshold for the two univariate tests, because ofcorrelations between LEP and ADIPOQ. If we can as-
sume that the two phenotypes are independent, we can
set a common threshold (roughly as 0.02532057) for
them. We then get 209 (11.32%) significant gene sets
tested by the naïve approach, but not including 67
(3.63%) of the 159 (8.61%) significant gene sets tested by
the multiple LCT. This indicates that naïve approach
can identify only gene sets associated with one of the
two multiple phenotypes, instead of their combination.
LCT methods rely on the linearity assumption. To
check the linearity assumption, exploratory data analysis
Wang et al. BMC Bioinformatics 2014, 15:260 Page 8 of 9
http://www.biomedcentral.com/1471-2105/15/260should be used prior to running a formal inference. How-
ever, a small sample size which is common in microarray
studies, would limit a thorough check for nonlinearities.
In the case of small sample size, we prefer using LCT in-
stead of NLCT. The latter is suitable for relatively larger
sample sizes and in the case linear assumption does not
hold. Our simulation and real microarray studies indicated
LCT methods perform very well for small sample sizes.
The question of how small is small is debatable and de-
pends largely on the study design. In the case of a binary/
categorical phenotype, at least five samples per group are
desirable. In the case of continuous phenotypes, assessing
significance based on less than 10 samples is dangerous;
an alternative would be to rely upon representations that
are more descriptive/exploratory in nature. In terms of
computation, both LCT and NLCT are highly efficient
compared to other GSA methods, especially given the in-
corporation of the covariance matrix into the estimations.
We noticed that high correlation among genes and/or
phenotypes enhances the testing power of LCT and
NLCT. To understand this phenomenon, we need to
distinguish correlation testing from regression model-
ing. In the later, we try to explain variance of the de-
pendent variable by a group of predictors. So it is better
for the predictors to be linearly independent, since high
correlation among them may reduce rank(X), i.e. the
real number of predictors. In the former, we are trying
to find two linear combinations of genes and phenotypes
respectively, with highest correlation between them. High
correlation among genes may reduce p = rank(X), i.e.
the real dimension of genes; and high correlation among
phenotypes may reduce q = rank(Y), i.e. the real dimen-
sion of phenotypes. The smaller the dimensions p
and q the easier to test the correlation between genes
and phenotypes.Conclusions
Our proposed LCT and NLCT approaches are effective
in controlling type I errors and powerful in testing as-
sociations between gene-sets and multiple continuous
phenotypes. They are both computationally effective.
Naively (univariately) analyzing a group of multiple cor-
related phenotypes, i.e., ignoring correlation structure
among phenotypes, could be dangerous.Availability and requirements
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